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Abstract
Background: Humans are the only host of polioviruses, thus the prospects of global polio eradication look reasonable. 
However, individuals with immunodeficiencies were shown to excrete vaccine derived poliovirus for long periods of 
time which led to reluctance to prolong the vaccination campaign for fear of this end result. Therefore, we aimed to 
assess the duration of excretion of poliovirus after the 2001 National Immunization Days according to Human 
immunodeficiency virus status.
Findings: Fifty three children were enrolled. Sequential stool samples were collected in between National 
Immunisation Days rounds and then every month during one year. Children were classified into 2 groups: no 
immunodepression (n = 38), immunodepression (n = 15) according to CD4+ lymphocytes cells count. Thirteen 
poliovirus strains were isolated from 11 children: 5 Human immunodeficiency virus positive and 6 Human 
immunodeficiency virus negative. None of the children excreted poliovirus for more than 4 weeks. The restriction 
fragment length polymorphism analysis showed that all strains were of Sabin origin including a unique Polio Sabine 
Vaccine types 2 and 3 (S2/S3) recombinant.
Conclusions: From these findings we assume that Human immunodeficiency virus positive children are not a high risk 
population for long term poliovirus excretion. More powerful studies are needed to confirm our findings.
Findings
Introduction
Humans are the only host of polioviruses, thus the pros-
pects of global polio eradication look reasonable [1,2].
However the discovery, after years of massive use of oral
polio vaccine (OPV), of individuals with immunodefi-
ciencies who were shown to excrete vaccine derived
poliovirus (VDPV) for long periods of time led to a reluc-
tance to prolong the vaccination campaign for fear of this
end result [3]. Considering the immunodeficiency that
prevails in Human immunodeficiency virus (HIV)
patients, long term poliovirus excretion would be likely
[4,5]. In Africa the OPV is used in mass vaccination cam-
paigns during National Immunization Days (NIDs) not-
withstanding HIV status of children. Two recent studies
showed that HIV-infected children have low persistence
of antibodies to vaccines used in the Expended Program
on Immunization (EPI) including OPV [6,7].
In Central African Republic (CAR), it have been
assessed that the prevalence of HIV infection is 6% in
general population [8] thus it would be of interest to
study the impact of HIV infection on poliovirus excretion
in infants of 0 to 5 years of age receiving OPV during
NIDs in Bangui. Very few studies have been conducted
and no persistent excretion of poliovirus has been
reported among HIV infected people [9,10] except two
vaccine derived polioviruses isolated from 2 HIV-
infected children in South Africa [4,5]. Therefore we
studied the duration of excretion of poliovirus after the
2001 NIDs according to HIV status.
Materials and methods
Population
This survey was achieved within "Foyer de Charité" cen-
ter from October 2001 until June 2002. This health struc-
ture is set up by the Catholic Church and take health care
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of the children descended of the very poor families in
return for a weak financial involvement (2 US$ per child).
All children included in this study were under 5 years old.
The informed consent of parents or legal tutors was
obtained before inclusion in the study. One blood sample
(for confirmation of HIV status and CD4+ count) and
stool samples were collected before NIDs. All enrolled
infants received 3 doses of OPV during the 3 rounds of
NIDs. Sequential stool samples were collected in between
NIDs rounds and then every month for one year period
from the enrolled children. HIV+ positives infants were
identified and followed up for opportunistic diseases at
this health care structure. Children who did not present
at the scheduled day were followed up at home when pos-
sible. All samples were processed at Institut Pasteur de
Bangui. The date of the last OPV dose administrated was
noted.
Status of human immunodeficiency virus-infected children
According to their HIV status and CD4+ count, the chil-
dren were classified into 2 groups: i) group A no immu-
nodepression (n = 38; 5 HIV+ and 11 HIV-); ii) group I
immunodepression (n = 15; 11 HIV+ and 4 HIV-). Chil-
dren less than 12 months of age were considered as
immunodepressed if the CD4+ count was <500/mm3,
and children of more than 12 months of age were consid-
ered immunodepressed if the CD4+ was <750/mm3 [11].
Western blot tests (new Lav blot I©, BioRad, Marne la
Coquette, France) were carried out at Institut Pasteur de
Bangui to confirm the HIV status of children. Tests were
performed using the same sample to determine the CD4
count. Haematological analysis and CD4 T-cell counts
were carried out with a Coulter AcT Diff 2 Analyser and a
FACSCalibur Flow Cytometer (Becton Dickinson Immu-
nocytometry Systems, San Jose, CA, USA), as previously
described [12].
Virus isolation and identification
Viruses were isolated and identified according to World
Health Organization (WHO) Polio Laboratory Network
Standard Protocols [13]. Internal quality-control proce-
dures associated with these methods were implemented.
Briefly, stool extracts were inoculated on the following
cell lines: RD (human rhabdomyosarcoma derived cells),
Hep2 (human epidermoid cancer cells) and murine L20B
(a transgenic mouse L cells). The latter cell line was used
to distinguish polioviruses from non-polio enteroviruses
[14]. Positive RD and Hep2 cell cultures were passaged in
L20B to separate poliovirus and non polio enteroviruses.
Isolates of poliovirus were identified by neutralization
tests with standardized pools of hyperimmune equine
serum. Tissue culture infectious dose can be determined,
using the double or triple cell-line system. The cells were
discarded every 15 passages, as recommended by WHO,
in order to ensure high cell sensitivity to enteroviruses
and especially for poliovirus. Sensitivity tests were con-
ducted at passage 7 by titration of reference Sabine
strains. If the titre is within ±0.5log10 of the expected ref-
erence value, it is considered that there is no decline in
cell-line sensitivity.
Reverse Transcriptase- Polymerase chain reaction (RT-PCR) 
and multiple restriction fragment length polymorphism 
(RFLP) analysis
Viral ribonucleic acid (RNA) was extracted using the
Quiaquick kit (QIAGEN®). Three different genomic
regions of the poliovirus genome, namely, VP3-VP1
(nucleotides positions 1913 to 2881 according to Sabin 1
numbering), VP1-2A (nucleotides 2870 to 3648) and 3D-
3'UTR (nucleotides 6536 to 7441) were targeted. RT-
PCR was followed by a multiple RFLP analysis using four
restriction enzymes (DdeI, DpnII, RsaI and HinfI). These
regions were amplified using nucleotides primers UG24
and UC1, UG19 and UC13 and UG17 and UC10 respec-
tively [15,16].
Statistical analysis
Data were managed using EpiInfo Software 3.3.2 version
(Centres for Disease Control and Prevention, USA).
Means of virus isolated were compared according to the
immune status of the patient using Mann-Whitney U
test.
Nucleotides sequencing analysis
Nucleotides sequencing of VP1-2A region PCR products
was performed with the same primers used for RT-PCR
and with internal primers UG1 and UC11. PCR products
were sequenced following purification with a Qiaquick
spin column purification kit (QIAGEN) immediately
after amplification. Sequencing reactions were performed
with a BigDye Terminator cycle sequencing ready kit
(version 1.1) according to the recommendations of
Applied Biosystems. Nucleotide sequences were aligned
and compared using Clustal W program [17].
Results
A total of 117 children were eligible before the first round
of the NIDs. Out of 117 children, 53 (45.3%) received the
all course of 3 OPV doses during of the NIDs (mean age,
56.3 months; male/female ratio, 0.8) and were enrolled in
the study.
HIV test was positive among 16 out of 53 (30.2%) chil-
dren and negative results were observed in 37 out of 53
(69.8%) children. From the 53 children who have received
3 doses of OPV, a total of 345 stools samples were col-
lected during the follow-up. The total number of stool
samples expected for each case was 10. But the number of
stools samples we collected significantly decreased dur-Manirakiza et al. BMC Research Notes 2010, 3:136
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ing the follow up because of no compliance to indicated
visits schedules and lost of follow up at home (home
changes to addresses not easily accessible). The mean of
the stool sample collected from each case was of 7 and 6
for the HIV+ and HIV- groups respectively (Figure 1).
A proportion of 36.8% of them were positive for an
enterovirus (127 viruses isolated from 345 stools). Six
poliovirus were isolated on the 107 stools colleted from
HIV+ children (5.6%) while five poliovirus were isolated
on the 238 stools colleted from HIV- children (2.1%) (P
value = 0.185). Non Polio Enteroviruses (NPE) were
excreted in a proportion of 31.8% (34/107) from all HIV+
children and 34.4% (82/238) from all HIV- children (P
value = 0.626) (Table 1).
Only two HIV- children excreted poliovirus before the
NIDs as they received the routine vaccination during the
month preceding the first stool sample collection.
Figure 1 Sequential stools collection flow chart from the cohort study from Day 0 of follow up.
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All the 15 children with immunodeficiency (group I)
secreted an Enterovirus, and 11 of them secreted a virus
more than two times. Thirty four out 38 children with no
i m m u n o d e f i c i e n c y  ( g r o u p  A )  s e c r e t e d  a n  E n t e r o v i r u s ,
and 13 of them secreted a virus more than two times.
None of the children excreted poliovirus for more than 4
weeks. Only two HIV- children excreted Poliovirus type 1
and 2 strains two times consecutively. There was no sta-
tistically significant difference of excretion of an Entero-
virus according to HIV serologic (Fisher exact test value =
0,069) and immune level status (U-test P values > 0,05 for
both HIV+ and HIV- groups) (Tables 1 and 22).
RFLP analysis showed that all strains were of Sabin ori-
gin, including a unique S3/S2 recombinant. Sequencing
of Poliovirus type 1 and Poliovirus type 3 strains, both
isolated from HIV+ infants, showed more than 99%
homology with homotypic Sabine strains.
Discussion
Literature reports that both cellular and humoral
immune responses are intact early in life in most children
infected with HIV [18,19]. Although HIV infected indi-
viduals may shed other enteric viruses for prolonged
periods, the lack of persistent poliovirus vaccine excre-
tion is consistent with their ability to develop immunity
after vaccination. Even after deterioration of CD4 cell
counts, these children retained sufficient immunologic
memory to prevent persistent infections from repeated
exposures to poliovirus [20,21].
The main aim of our study was to evaluate the risk of
prolonged OPV circulation in a population of children
receiving massive doses of OPV accordingly to their HIV
status. Our findings showed no trend of a prolonged
Poliovirus excretion in HIV+ and HIV- children groups.
The relatively small size of the cohort does not allow
exclusion of the possibility that a small proportion of HIV
infected children may develop prolonged excretion, espe-
cially since antiretroviral treatments were introduced in
CAR and prolonged the duration of life of these children.
Studies conducted on 28 HIV-infected adults popula-
tion exposed to vaccinated children in CAR and 419
adults in Cote d'Ivoire following anti-poliovirus vaccina-
tion campaigns showed no evidence of prolonged Entero-
virus excretion [9,10].
In most industrialized countries, inactivated polio vac-
cine (IPV) is administrated to individuals with immuno-
deficiency disorders because the potential risk of vaccine
associated paralytic poliomyelitis (VAPP). Nevertheless,
the limited data available indicate a risk of VAPP in chil-
dren with HIV and OPV which is generally administrated
to all children regardless their HIV status in low income
countries [4,5]. In the past 40 years only 23 persons with
IgG deficiency disorders have been found with prolonged
poliovirus excretion. Active search for additional persons
with prolonged poliovirus excretion among persons with
known IgG deficiency disorders revealed no new cases
[3,22].
Conclusion
The small size of the cohort do not allow us to draw a
definitive conclusion, but indicates that excretion of
poliovirus among HIV infected children is present and
Table 1: Viruses isolated according to sample collection session and HIV status from the study cohort (53 children).
Non polio enteroviruses Poliovirus Negative
HIV+ HIV- HIV+ HIV- HIV+ HIV-
A8 1 6 028 1 9
B 3 14 1 2 12 21
C2820 1 2 2 9
D26316 1 9
E4 1 2 008 2 0
F6 1 4 006 1 5
G54005 1 8
H030068
I450031
J000011
T o t a l 3 4 8 26 56 7 1 5 1
A = sample collection before NID's: Day 0, B= sample collection between the 1st and 2nd round of NID's (Day 15), C= sample collection between 
the 2nd and 3rd round (Day 45), D, E, F, G, H, I, J = sequential sample collection after the 3rd round at one.Manirakiza et al. BMC Research Notes 2010, 3:136
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such short term excretion is unlikely to be a source of
reintroduction of neurovirulent poliovirus following the
cessation of OPV use in Central African Republic. More
powerful studies are needed to confirm our findings.
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